Global Non-Small Cell Lung Cancer Market, By Cancer Type (Non-Small Cell Lung Cancer, Metastatic Lung Cancer, Pulmonary Neuroendocrine Tumours, Mediastina Tumours, Mesothelioma and Chest Wall Tumours), Molecule Type (Small Molecules and Biologics), Drug Class (Alkylating Agents, Antimetabolites, EGFR Inhibitors, Mitotic Inhibitors, Multi-kinase Inhibitors and Others), Treatment Type (Chemotherapy, Radiation Therapy, Targeted Therapy, Immunotherapy and Others), Therapy Type (Single Drug Therapy and Combination Therapy), End User (Hospitals, Homecare, Specialty Clinics and Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online and Others), Country (U.S., Canada, Mexico, Peru, Brazil, Argentina, Rest of South America, Germany, Italy, U.K., France, Spain, Netherlands, Belgium, Switzerland, Turkey, Russia, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia Pacific, South Africa, Saudi Arabia, U.A.E, Kuwait, Israel, Egypt, Rest of Middle East and Africa) Industry Trends and Forecast to 2028
Rising cases of cancer coupled with rising awareness regarding the health of patients are attributable to the growth of non-small cell lung cancer market. Data Bridge Market Research analyses that the non-small cell lung cancer will exhibit a CAGR of around 10.91% for the forecast period of 2021-2028.
One of the major types of lung cancer, a non-small cell lung cancer is the one that decreases the efficiency of lungs to supply oxygen to the blood. Out of the entire lung cancer cases globally, non-small cell lung cancer accounts for 80-85%. The factors responsible for this are passive smoking, active smoking, consumption of contaminated water and exposure to air pollution. However, it can be treated by various therapies such as immunotherapy, targeted therapy and much more.
Excessive consumption of tobacco and active engagement in passive smoking are the two major factors responsible for non-small cell lung cancer. Long-time exposure to air pollution bolsters the growth of non-small cell lung cancer. Rising investment by the major key players of research and development activities will further foster market growth. Rising geriatric population susceptible to cancer will further contribute to the global non-small cell lung cancer market share.
However, presence of major players and entrance of new key players will lead to excessive competition in the market. This would result in slowing down the lung cancer therapeutics market growth rate. High cost of therapy or treatment will further restrain the scope of growth.
This non-small cell lung cancer market report provides details of new recent developments, trade regulations, import export analysis, production analysis, value chain optimization, market share, impact of domestic and localised market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on non-small cell lung cancer market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Global Non-Small Cell Lung Cancer Market Scope and Market Size
The non-small cell lung cancer market is segmented on the basis of cancer type, molecule type, drug class, treatment type, therapy type, end user and distribution channel. The growth amongst these segments will help you analyse meagre growth segments in the industries, and provide the users with valuable market overview and market insights to help them in making strategic decisions for identification of core market applications.
- Based on the cancer type, the non-small cell lung cancer market has been segmented into non-small cell lung cancer, metastatic lung cancer, pulmonary neuroendocrine tumours, mediastina tumours, mesothelioma and chest wall tumours.
- Based on the molecule type, the non-small cell lung cancer market has been segmented into small molecules and biologics.
- On the basis of drug class, the non-small cell lung cancer market is segmented into alkylating agents, antimetabolites, EGFR inhibitors, mitotic inhibitors, multi-kinase inhibitors and others.
- On the basis of treatment type, the non-small cell lung cancer market is segmented into chemotherapy, radiation therapy, targeted therapy, immunotherapy and others. Targeted therapy is further sub-segmented into bevacizumab, dabrabenib, erlotinib hydrochloride, osimertinib and others. Immunotherapy is also sub-segmented into durvalumab, nivolumab, atezolizumab and pembrolizumab.
- On the basis of therapy type, the non-small cell lung cancer market is segmented into single drug therapy and combination therapy.
- On the basis of end user, the non-small cell lung cancer market is segmented into hospitals, homecare, speciality clinics and others.
- On the basis of distribution channel, the non-small cell lung cancer market is segmented into direct hospital pharmacy, retail pharmacy, online and others.
Core Non-Small Cell Lung Cancer Market Country Level Analysis
The non-small cell lung cancer market is analysed and market size insights and trends are provided by country, cancer type, molecule type, drug class, treatment type, therapy type, end user and distribution channel as referenced above.
The countries covered in the non-small cell lung cancer market report are U.S., Canada and Mexico in North America, Peru, Brazil, Argentina and Rest of South America as part of South America, Germany, Italy, U.K., France, Spain, Netherlands, Belgium, Switzerland, Turkey, Russia, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe in Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific (APAC) in Asia-Pacific (APAC), South Africa, Saudi Arabia, U.A.E, Kuwait, Israel, Egypt, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA).
North America dominates the non-small cell lung cancer market owing to the prevalence of sophisticated healthcare infrastructure, increased research and development proficiencies by the pharmaceutical companies and rapid adoption of new and better healthcare technologies. Asia-Pacific on the other hand is projected to score highest growth rate for the forecast period owing to rising expenditure to develop healthcare infrastructure, rising prevalence of non-small cell lung cancer and rising geriatric population susceptible to cancer.
The country section of the non-small cell lung cancer market report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as consumption volumes, production sites and volumes, import export analysis, price trend analysis, cost of raw materials, down-stream and upstream value chain analysis are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Healthcare Infrastructure growth Installed base and New Technology Penetration
The non-small cell lung cancer market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for clinical trial imaging market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the non-small cell lung cancer market. The data is available for historic period 2010 to 2019.
Competitive Landscape and Non-Small Cell Lung Cancer Market Share Analysis
The non-small cell lung cancer market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies’ focus related to core non-small cell lung cancer market.
The major players covered in the non-small cell lung cancer market report are GlaxoSmithKline plc., F. Hoffmann-La Roche Ltd, Novartis AG, Eli Lilly And Company., Astrazeneca, Pfizer Inc., Takeda Pharmaceutical Company Limited., Ono Pharmaceutical Co., Ltd., Boehringer Ingelheim International Gmbh, Merck & Co., Inc., Celgene Corporation, Amgen Inc., Sanofi, Johnson & Johnson Services, Inc., Sun Pharmaceutical Industries Ltd., Dr. Reddy’s Laboratories Ltd., Allergan, Teva Pharmaceutical Industries Ltd., Bristol-Myers Squibb Company and Astellas Pharma Inc. among other domestic and global players. Market share data is available for Global, North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South America separately. DBMR analysts understand competitive strengths and provide competitive analysis for each competitor separately.
Customization Available : Global Non-Small Cell Lung Cancer Market
Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customised to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analysed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Factbook) or can assist you in creating presentations from the data sets available in the report.